Vivodyne
-
Business & Markets · Enterprise Vivodyne to Replace Animal Testing With $40M Funding to Reverse 95% Clinical Trial Failure Rate
Insider Brief PRESS RELEASE — Biopharmaceutical companies routinely cure diseases in animals during preclinical testing, yet those same therapies fail in human clinical trials nearly 95% of the time. By shifting from animals to an exclusively… -
Business & Markets · Startups Vivodyne Announces $38M Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs
The AI economy, every weekday morning
The daily briefing plus the weekly Scale-ups to watch edition. Free, no spam, unsubscribe any time.